Contribute
España
Italia
대한민국
日本
Français

Benzinga

Research
My Stocks
Tools
Free Benzinga Pro Trial

Needham

Block Posts Blowout Q1 On Cash App Strength; Raised Outlook Reflects Improvement In 2026, Analysts Say
Block Posts Blowout Q1 On Cash App Strength; Raised Outlook Reflects Improvement In 2026, Analysts Say
Datadog Rips Higher As AI Customers Fuel Revenue Acceleration
Datadog Rips Higher As AI Customers Fuel Revenue Acceleration
Recursion Eyes Breakthrough With REC-4881 Drug For Rare Genetic Condition, But Shares Pull Back
Recursion Eyes Breakthrough With REC-4881 Drug For Rare Genetic Condition, But Shares Pull Back
Datadog Rips Higher As AI Customers Fuel Revenue Acceleration
Datadog Rips Higher As AI Customers Fuel Revenue Acceleration
Recursion Eyes Breakthrough With REC-4881 Drug For Rare Genetic Condition, But Shares Pull Back
Recursion Eyes Breakthrough With REC-4881 Drug For Rare Genetic Condition, But Shares Pull Back
Uber Zooms Ahead On Platform Strength, Analysts Revise Estimates After Q1 Print
Uber Zooms Ahead On Platform Strength, Analysts Revise Estimates After Q1 Print
This Hut 8 Analyst Raises Price Target Despite Q1 Miss
This Hut 8 Analyst Raises Price Target Despite Q1 Miss

Needham Recent News

Duolingo Posts Q1 Beat; Faces Softness In Monthly Active User Growth
Duolingo Posts Q1 Beat; Faces Softness In Monthly Active User Growth
Duolingo stock drops despite upbeat Q1 results. DAU growth exceeded 20% target. MAU growth decelerated and came in softer than expected.
Streaming Strength, Stock Strain: Paramount Skydance's Hit Quarter Comes With A Plot Twist
Streaming Strength, Stock Strain: Paramount Skydance's Hit Quarter Comes With A Plot Twist
Paramount Skydance posts Q1 DTC revenue growth. Expects this to continue into Q2 and possibly close WBD acquisition in September.
Vertex Pharmaceuticals Posts Mixed Q1; Investors Focus On Non-CF Pipeline For Growth
Vertex Pharmaceuticals Posts Mixed Q1; Investors Focus On Non-CF Pipeline For Growth
Vertex Pharma posts revenue beat but misses EPS expectations. CF franchise remains strong, says Needham analyst.
Reddit Rallies As Ad Growth Drowns Out User Miss
Reddit Rallies As Ad Growth Drowns Out User Miss
Shares of Reddit surged on Friday after the company reported solid Q1 results and announced strong guidance.
Roku Rewinds Doubters With Ad-Fueled Earnings Beat
Roku Rewinds Doubters With Ad-Fueled Earnings Beat
Shares of Roku rallied after Q1 beat and guidance raise. Analysts hiked their PTs on increased adoption of Roku's OS.
Amazon Stock Falls On Earnings Despite AWS 'Growing At Its Fastest Clip In 4 Years'
Amazon Stock Falls On Earnings Despite AWS 'Growing At Its Fastest Clip In 4 Years'
Amazon analysts raise their price targets after Q1 results and a backlog update.
Cadence Design Systems Posts Q1 Beat: Agentic AI Garners Momentum, Say Bullish Analysts
Cadence Design Systems Posts Q1 Beat: Agentic AI Garners Momentum, Say Bullish Analysts
Cadence Design Systems posts strong Q1 results and raises 2026 revenue guidance to $6.125-$6.225 billion.
Intel Reports Q1 Beat, Yet These Analysts Remain Bearish
Intel Reports Q1 Beat, Yet These Analysts Remain Bearish
Intel's shares rally after reporting upbeat Q1 results. Analysts remain bearish on earnings quality and subpar margins.
ServiceNow Shares Fall As Middle East Delays, Soft Guidance Weigh On Outlook
ServiceNow Shares Fall As Middle East Delays, Soft Guidance Weigh On Outlook
ServiceNow stock tanks despite Q1 beat. Q2 guidance, delayed Middle East deals impact investor sentiment. Four analysts cut PT.
MapLight's Psychosis Drug Could Deliver Billion-Dollar Upside, Says Analyst
MapLight's Psychosis Drug Could Deliver Billion-Dollar Upside, Says Analyst
Needham initiates MapLight with Buy, citing ML-007C-MA potential in schizophrenia and AD psychosis, with key readouts expected through 2027.
Nike Stock Plunges As Weak China Sales Guidance Rattles Investors
Nike Stock Plunges As Weak China Sales Guidance Rattles Investors
Nike beats Q3 EPS, but faces challenges in turnaround. NA sales grow 3%, China sales down 10%, EMEA performance was worse than expected.
Centessa Pharmaceuticals Agrees To Eli Lilly Acquisition At 40% Premium
Centessa Pharmaceuticals Agrees To Eli Lilly Acquisition At 40% Premium
Centessa Pharma to be acquired by Eli Lilly for $8B. Analyst downgrades rating. Deal includes $6.3B in cash and potential $1.5B in milestones.
Oklo Ramps Up Spending As July 4 Deadline Looms: Is The Nuclear Startup Ready For Its Big Test?
Oklo Ramps Up Spending As July 4 Deadline Looms: Is The Nuclear Startup Ready For Its Big Test?
Oklo reported Q4 results. Company raised $1.2B and has $2.6B in liquidity. Projects on track for future growth. Analysts reiterate Buy.
Semtech Beats Q4 Expectations, Analyst Says AI Data Center Demand Outpaces Legacy Business Model
Semtech Beats Q4 Expectations, Analyst Says AI Data Center Demand Outpaces Legacy Business Model
Semtech shares dropped after Q4 results. Analysts remain bullish even as investors remain concerned about datacenter inflection.
DocuSign Q4 Preview: AI Twist Takes Center Stage As Company Pivots Beyond Signatures
DocuSign Q4 Preview: AI Twist Takes Center Stage As Company Pivots Beyond Signatures
Docusign Q4 earnings likely to meet expectations with positive trends in IAM and consistent Esignature demand.
Why Are HubSpot Shares Climbing On Thursday?
Why Are HubSpot Shares Climbing On Thursday?
HubSpot (NYSE: HUBS) shares are up on Thursday. Despite a lack of new headlines, investors appear to be digesting recent Q4 beats and positive 2026 growth drivers.
Unusual Machines Posts 130% Revenue Growth Due To US Drone Supercycle: Analyst
Unusual Machines Posts 130% Revenue Growth Due To US Drone Supercycle: Analyst
UMAC reported strong Q4 results, with 130% YoY revenue growth. The company is well positioned to benefit from US drone dominance initiative.
AtaiBeckley: Lead Candidate Could Be Game-Changer For TRD Patients, Say Analysts
AtaiBeckley: Lead Candidate Could Be Game-Changer For TRD Patients, Say Analysts
AtaiBeckley's lead candidate, BPL-003, showed promising results in TRD. Analysts expect it to be a game changer and command premium pricing.
Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved